The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
August 26th 2025
GLP-1 receptor agonists like semaglutide show promise in reducing obesity-related cancer risks, while highlighting the need for ongoing safety monitoring.
FDA Expands Approval of Stivarga for Liver Cancer
April 27th 2017The FDA has expanded the approved use of Stivarga (regorafenib, Bayer HealthCare Pharmaceuticals Inc.) to include the treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.
Read More